- Home
- HYNE vs ALDX Comparison
HYNE vs ALDX Comparison
Compare HYNE & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HYNE | ALDX |
|---|---|---|
| Founded | 2025 | 2004 |
| Country | United States | United States |
| Employees | 61 | N/A |
| Industry | Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 121.5M | 103.1M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | HYNE | ALDX |
|---|---|---|
| Price | $16.36 | $2.05 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $5.50 |
| AVG Volume (30 Days) | 23.9K | ★ 1.1M |
| Earning Date | 05-14-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 40.43 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.56 | $1.07 |
| 52 Week High | $16.65 | $6.18 |
Technical Indicators
Market Signals| Indicator | HYNE | ALDX |
|---|---|---|
| Relative Strength Index (RSI) | 65.81 | 65.79 |
| Support Level | $16.11 | $1.49 |
| Resistance Level | N/A | $2.33 |
| Average True Range (ATR) | 0.16 | 0.15 |
| MACD | 0.02 | 0.04 |
| Stochastic Oscillator | 69.09 | 79.82 |
Price Performance
Historical ComparisonAbout HYNE Hoyne Bancorp Inc.
Hoyne Bancorp Inc is a holding company that conducts business mainly through its subsidiaries. It is a savings institution focused on serving customers' banking needs in the market area. The group offers Personal and Business banking services.
About ALDX Aldeyra Therapeutics Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma, and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.